Richard Heyman

RayzeBio is a pharmaceuticals company that develops targeted radiopharmaceutical drugs for cancer.

Raised $418,000,000.00 from Soleus Capital, Ally Bridge Group, Viking Global Investors, Laurion Capital Management, Wellington Management, Sands Capital Ventures and Sofinnova Investments.

Curebound raises and invests funds in cancer research, focusing on translational projects to develop new treatments and cures.

Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.

Raised $230,000,000.00 from Acuta Capital Partners, Venrock Healthcare Capital Partners, Commodore Capital, Rock Springs Capital, Logos Capital, Fairmount Funds Management and Woodline Partners.

PMV Pharmaceuticals is a developer of p53-targeted small molecule drugs for the treatment of cancer.

Raised $236,000,000.00 from Viking Global Investors, Nextech Invest, RA Capital Management, Avoro Capital Advisors, OrbiMed, Boxer Capital and Wellington Management.

ARCH is a venture firm that focuses on life science discoveries to prevent, detect, and cure disease.

Vividion is a developer of a novel drug discovery platform designed to offer transformative treatments to patients with serious illnesses.

Raised $371,504,616.00 from Woodline Partners, Avoro Capital Advisors, Logos Capital, SoftBank Vision Fund, Boxer Capital, Acuta Capital Partners, T. Rowe Price, Surveyor Capital, Nextech Invest and Driehaus Capital Management.

Salk Institute for Biological Studies conducts research on molecular biology and genetics, neurosciences, and plant biology.

Raised $81,400,000.00 from California Institute for Regenerative Medicine, The Audacious Project, Alzheimer's Research UK, National Institutes of Health and The Leona M. and Harry B. Helmsley Charitable Trust.